Century TherapeuticsIPSC
About: Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
Employees: 165
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1,700% more call options, than puts
Call options by funds: $18K | Put options by funds: $1K
129% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 14
11.44% more ownership
Funds ownership: 36.31% [Q1] → 47.75% (+11.44%) [Q2]
5% more capital invested
Capital invested by funds: $98.4M [Q1] → $103M (+$4.52M) [Q2]
8% less funds holding
Funds holding: 66 [Q1] → 61 (-5) [Q2]
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Mitchell Kapoor 50% 1-year accuracy 66 / 131 met price target | 614%upside $9 | Buy Maintained | 15 Aug 2024 |